The MARIPOSA-2 trial (NCT04988295) showed that combining amivantamab with chemotherapy, with or without lazertinib, improved PFS alone in EGFR-mutant NSCLC patients who had progressed after osimertinib therapy.120. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.